Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Aug 19, 2024 9:30am

181 Views

Post# 36185660

Canadian Clinical Site Approvals too Long

Here is another article below on the approval process for clinical trials done in Canada.

The approval process takes 6-12 months.

We announced our Canadian sites in March & April 2024 so we are 4-5 months into the process.

We potentially could be looking into spring of 2025 before dosing starts in Canada or potentially never even dosing in Canada as we are currently dosing at 5 sites in Turkey.

Now all of this approval process is out of the control of Arch.

This is another reason we have a bullseye on our back and been attacked by algorithm short traders.

One needs to think how this lengthy process impacts our announced Pontiac Trial slated for fall of 2024. I would not be banking on it starting until later 2025 based on what I am reading.

There were many trials planned for covid that never even got to dosing due to the lengthy approval process.

https://www.cmaj.ca/content/195/14/E517